Tissue factor pathway inhibitor‐2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma

Chun‐Ming Wong, Yeung‐Lam Ng, Joyce Man‐Fong Lee, Carmen Chak‐Lui Wong, Oi‐Fung Cheung, Chung‐Yiu Chan, Edmund Kwok‐Kwan Tung, Yick‐Pang Ching, Irene Oi‐Lin Ng – 26 April 2007 – In HCC, inactivation of tumor suppressor genes plays a significant role in carcinogenesis. Apart from deletions and mutations, growing evidence has indicated that epigenetic alterations including aberrant promoter methylation and histone deacetylation are also implicated in inactivation of tumor suppressor genes.

Increased activity of hepatic microsomal triglyceride transfer protein and bile acid synthesis in gallstone disease

Juan Castro, Ludwig Amigo, Juan Francisco Miquel, Cecilia Gälman, Fernando Crovari, Alejandro Raddatz, Silvana Zanlungo, Roberto Jalil, Mats Rudling, Flavio Nervi – 26 April 2007 – A strong interrelationship exists between the regulation of bile acid (BA) metabolism and hepatic very low density lipoprotein (VLDL) production. We have recently shown that BA synthesis is increased in gallstone disease.

Met signals hepatocyte survival by preventing Fas‐triggered FLIP degradation in a PI3k‐Akt–dependent manner

Anice Moumen, Alessandro Ieraci, Salvatore Patané, Carme Solé, Joan X. Comella, Rosanna Dono, Flavio Maina – 26 April 2007 – The FasL‐Fas couple is a general death mediator whose activated signals lead to caspase‐8 activation and apoptosis in adult hepatocytes. Suppression of caspase‐8 activation and cell death is a protective mechanism modulated by the FLICE‐Like Inhibitory Protein (FLIP). Although hepatocyte growth factor (HGF) and its receptor Met are known to mediate cell survival in developing livers, the molecular mechanisms involved in this process are poorly understood.

Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine

Tsuyoshi Hatakeyama, Chiemi Noguchi, Nobuhiko Hiraga, Nami Mori, Masataka Tsuge, Michio Imamura, Shoichi Takahashi, Yoshiiku Kawakami, Yoshifumi Fujimoto, Hidenori Ochi, Hiromi Abe, Toshiro Maekawa, Hiroiku Kawakami, Hiromi Yatsuji, Yasuyuki Aisaka, Hiroshi Kohno, Shiomi Aimitsu, Kazuaki Chayama – 26 April 2007 – Lamivudine (LAM) is a nucleoside analogue widely used for the treatment of chronic hepatitis B virus (HBV) infection.

Racial disparities in the management of hospitalized patients with cirrhosis and complications of portal hypertension: A national study

Geoffrey C. Nguyen, Dorry L. Segev, Paul J. Thuluvath – 26 April 2007 – Having complications of portal hypertension is a harbinger of decompensated cirrhosis and warrants consideration for liver transplantation (LT). Racial disparities in LT have been reported. We sought to characterize disparities in the performing of surgical and endoscopic procedures among hospitalized patients with complications of portal hypertension. We queried the Nationwide Inpatient Sample from 1998 to 2003 to identify patients with cirrhosis and complications of portal hypertension.

Liver stiffness measurement predicts severe portal hypertension in patients with HCV‐related cirrhosis

Francesco Vizzutti, Umberto Arena, Roberto G. Romanelli, Luigi Rega, Marco Foschi, Stefano Colagrande, Antonio Petrarca, Stefania Moscarella, Giacomo Belli, Anna Linda Zignego, Fabio Marra, Giacomo Laffi, Massimo Pinzani – 26 April 2007 – Measurement of hepatic venous pressure gradient (HVPG) is a standard method for the assessment of portal pressure and correlates with the occurrence of its complications. Liver stiffness measurement (LSM) has been proposed as a noninvasive technique for the prediction of the complications of cirrhosis.

Subscribe to